Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) will host an investor conference call at 8:00 am ET on Tuesday, May 12, 2026 to review first quarter 2026 financial results. Senior management will provide an overview of quarterly financial performance via live audio webcast.
A replay and the earnings press release will be available in the Investor Relations section under Events and Presentation approximately two hours after the call concludes.
Positive
- None.
Negative
- None.
News Market Reaction – LEGN
In the Apr 28 session, LEGN declined 0.38%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Earnings call notice | Neutral | -1.3% | Scheduled Q4 and full-year 2025 earnings call with webcast details. |
| Oct 29 | Earnings call notice | Neutral | -1.4% | Announced Q3 2025 results conference call and replay availability. |
| Jul 28 | Earnings call notice | Neutral | -4.3% | Set date and time for Q2 2025 earnings call and webcast access. |
| Apr 29 | Earnings call notice | Neutral | -0.8% | Outlined logistics for Q1 2025 earnings call for investors. |
| Feb 25 | Earnings call notice | Neutral | +0.1% | Announced Q4 and full-year 2024 earnings call timetable and webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Similar conference-call scheduling headlines have historically coincided with modest share pressure, with average next-day moves around -1.52% on these announcements.
Over the past year, Legend Biotech has regularly pre-announced earnings calls, with five prior conferences,earnings notices since Feb 25, 2025. These events typically outline timing and webcast access, and have produced small, often negative, price moves around the news. Alongside this pattern, more substantive updates, such as Q4 2025 results and CARVYKTI data, have driven larger swings, framing today’s Q1 2026 call notice as part of a recurring cadence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12, 2026, to review first quarter 2026 financial results.
During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance.
Investors and other interested parties may access the live audio webcast via this weblink.
A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentation approximately two hours after the conclusion of the call.
ABOUT LEGEND BIOTECH
With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
media@legendbiotech.com
